Ligand Pharmaceuticals Inc.

519 articles about Ligand Pharmaceuticals Inc.

• Ligand Reports Second Quarter 2022 Financial Results

  8/8/2022

  Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates.

• Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Ligand Pharmaceuticals Incorporated announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units and 4,000 performance stock units to six non-executive employees.

• Ligand to Report Second Quarter Financial Results on August 8, 2022

  7/22/2022

  Ligand Pharmaceuticals Incorporated will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

• Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

  6/29/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jason Haas to the Company's Board of Directors.

• Ligand Reports First Quarter 2022 Financial Results

  5/4/2022

  Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates.

• Ligand to Report First Quarter Financial Results on May 4

  4/19/2022

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

• Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  Ligand Pharmaceuticals Incorporated announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock to Kurt Gustafson, who joined OmniAb, Inc., Ligand’s antibody discovery business, as its CFO, in connection with his commencement of employment.

• 

  Ligand's New Antibody Business Prepares to Hit the Nasdaq

  3/24/2022

  Ligand will spin off its antibody discovery business into a new entity known as OmniAb, Inc., which will then merge with Avista Capital Partners and head to The Nasdaq Stock Market. 

• Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

  3/23/2022

  Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ: LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC.

• Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

  2/17/2022

  Ligand Pharmaceuticals Incorporated reported financial results for the three and 12 months ended December 31, 2021, and provided an operating forecast and business updates.

• Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

  12/22/2021

  Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly ® ) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy.

• Ligand and GSK Expand Global Collaboration and License Agreement

  12/21/2021

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK).

• 

  Poseida Goes All-In on Allogeneic CAR-T; Ligand Explores Spin-Off

  11/10/2021

  Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.

• Ligand Reports Third Quarter 2021 Financial Results

  11/9/2021

  Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates.

• Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

  11/9/2021

  Ligand Pharmaceuticals Incorporated announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand’s existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business.

• Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

  10/21/2021

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand’s BEPro technology.

• Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

  8/30/2021

  Ligand Pharmaceuticals Incorporated today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).

• Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

  8/16/2021

  Ligand Pharmaceuticals Incorporated announces that its partner Travere Therapeutics, Inc. today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).

• Ligand Reports Second Quarter 2021 Financial Results

  7/29/2021

  Ligand Pharmaceuticals Incorporated reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates.

• Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

  7/21/2021

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™